The Cholinergic Profile as a Target for Rational Therapy of Central Nervous System Diseases and Injuries

Objective. To conduct a comparative analysis of the clinical efficacy of cholinergic drugs and acetylcholinesterase inhibitors and their combinations in the complex therapy of cerebrovascular pathology and the sequelae of closed craniocerebral trauma (cCCT) using clinical, instrumented, and laboratory follow-up investigations. Materials and methods. A total of 90 patients with cerebrovascular pathology (chronic cerebral ischemia grade 2 (I67; 45 patients) and the sequelae of cCCT (T90; 45 patients) were studied. Groups were divided into three subgroups each of 15 patients. Complex treatment included basal and specific therapy: subgroup 1 received the drug Neuromidin, group 2 received Gliatilin, and group 3 received Neuromidin plus Gliatilin. Treatment duration was two months. All patients underwent complex clinical, neurophysiological, and laboratory investigations before treatment and at one and two months from treatment initiation: plasma cholinesterase activity was estimated, patients were tested on the Mini Mental State Examination (MMSE) and the Hamilton scale, and patients underwent transcranial magnetic stimulation with assessment of the central motor conduction time and evaluation of somatosensory evoked potentials with determination of the central afferent conduction time. Results. Before treatment, a strong positive correlational relationship was found between patients’ age and serum cholinesterase activity (Rs = 0.77; p = 0.0001). On the background of treatment, all study parameters showed significant (p < 0.05) improvements with the exception of the MMSE, which showed only a trend to improvement) in subgroups 1 and 3 of each group as compared with values obtained in subgroups 2 of the corresponding groups. In addition, at two months from treatment initiation, there were significant decreases in serum cholinesterase activity in patients of subgroups 1 and 2. Conclusions. Assessment of deviations in the “cholinergic profile” (blood cholinesterase activity) in patients with cerebral pathology and the strategy of using cholinergic drugs and acetylcholinesterase inhibitors and their combination to correct psychoneurological disorders is among the most important directions in optimizing the combined treatment of patients of this category.

This is a preview of subscription content, log in to check access.


  1. 1.

    V. M. Shklovskii, “Neurorehabilitation of patients with the sequelae of stroke and craniocerebral trauma,” Zh. Nevrol. Psikhiat., Spec. Iss., 115, No. 3, 75–81 (2015),

  2. 2.

    Y. Sugiura, N. Zaima, M. Setou, et al., “Visualization of acetylcholine distribution in central nervous system tissue sections by tandem imaging mass spectrometry,” Anal. Bioanal. Chem., 403, No. 7, 1851–1861 (2012),

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    V. Benagiano, D. Virgintino, P. Flace, et al., “Choline acetyltransferase-containing neurons in the human parietal neocortex,” Eur. J. Histochem., 47, 253–256 (2003).

    CAS  Article  Google Scholar 

  4. 4.

    G. A. Reid, N. Chilukuri, and S. Darvesh, “Butyrylcholinesterase and the cholinergic system,” Neuroscience, 234, 53–68 (2013),

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    B. D. Drever, G. Riedel, and B. Platt, “The cholinergic system and hippocampal plasticity,” Behav. Brain Res., 221, 505–514 (2011),

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    N. I. Bohnen, M. Grothe, N. Ray, et al., “Recent advances in cholinergic imaging and cognitive decline – Revisiting the cholinergic hypothesis of dementia,” Curr. Geriatr. Rep., 7, No. 1, 1–11 (2018),

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    N. Richter, I. Allendorf, O. A. Onur, et al., “The integrity of the cholinergic system determines memory performance in healthy elderly,” NeuroImage, 100, 481–488 (2014),

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    N. I. Bohnen, D. I. Kaufer, R. Hendrickson, et al., “Cognitive correlates of alterations in acetylcholinesterase in Alzheimer’s disease,” Neurosci. Lett., 380, No. 1–2, 127–132 (2005),

  9. 9.

    G. A. Jackson, “Drug treatments for Alzheimer’s disease,” Nurs. Times, 110, 9:24–26 (2014).

    PubMed  Google Scholar 

  10. 10.

    I. V. Damulin, “The use of ipidacrine (Axamon) in neurological practice,” Trudnyi Patsient, 11, No. 5, 15–20 (2007).

    Google Scholar 

  11. 11.

    H. Forstl, A. Burns, R. Levy, et al., “Neuropathological correlates of behavioural disturbance in confirmed Alzheimer’s disease,” Br. J. Psychiatry, 163, 364–368 (1993),

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Lokshina, A. B., “Management of patients with dementia: cholinergic deficit and its correction,” Meditsinsk. Sov., 12, 30–35 (2018).

    Article  Google Scholar 

  13. 13.

    V. V. Gnezditskii and O. S. Korepina, Atlas of Evoked Potentials (a Practical Guide Based on Analysis of Specific Clinical Observations), PresSto, Ivanovo (2011).

  14. 14.

    S. S. Nikitin and A. L. Kurenkov, Methodological Bases of Transcranial Magnetic Stimulation in Neurology and Psychiatry. Guidelines for Doctors, Moscow (2006).

  15. 15.

    T. Iizuka and M. Kameyama, “Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer’s disease,” Geriatr. Gerontol. Int., 17, No. 6, 951–958 (2017),

    Article  PubMed  Google Scholar 

  16. 16.

    S. L. Risacher, B. C. McDonald, E. F. Tallman, et al., “Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults,” JAMA Neurol., 73, No. 6, 721–732 (2016),

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Y. S. Mineur and M. R. Picciotto, “Nicotine receptors and depression: Revisiting and revising the cholinergic hypothesis,” Trends. Pharmacol. Sci., 31, No. 12, 580–586 (2010),

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    S. A. Zhivolupov, I. N. Samartsev, and Yu. S. Butakova, “The current paradigm for the rational treatment of strokes,” Zh. Nevrol. Psikhiat. (Stroke), 8, No. 2, 82–87 (2016),

  19. 19.

    M. Pohanka, “Acetylcholinesterase inhibitors; a patent review (2008-present),” Exp. Opin. Ther. Pat., 8, 871–886 (2012),

Download references

Author information



Corresponding author

Correspondence to I. V. Litvinenko.

Additional information

Translated from, Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 120, No. 2, Iss. 1, pp. 31–38, February, 2020.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Litvinenko, I.V., Zhivolupov, S.A., Samartsev, I.N. et al. The Cholinergic Profile as a Target for Rational Therapy of Central Nervous System Diseases and Injuries. Neurosci Behav Physi (2020).

Download citation


  • cholinergic drugs
  • acetylcholinesterase inhibitors
  • impaired cognitive functions
  • Neuromidin
  • Gliatilin